This site is intended for U.S. Healthcare Professionals.

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Request a Rep

Review and download helpful resources about ONUREG® for acute myeloid leukemia

Resources for healthcare providers

ONUREG Clinical Brochure

Read all about ONUREG for patients in first AML remission


Review the ONUREG Brochure

ONUREG Dosing Guide

Get clear guidance on ONUREG dosing and dose modifications to help manage adverse reactions

Review the Dosing Guide

Patient Profiles

Meet patients with AML who may be similar to patients in your own practice


Review the Patient Profiles

Transitions of Care Guide

Get tips for supporting patients throughout their AML treatment journey

Review the Care Guide

Prescribing Information

Review the full US Prescribing Information for ONUREG

Review the Prescribing Information

 How to Order and Access ONUREG

Get details for ordering ONUREG, and learn how BMS supports patient access

Review the Ordering Guide

Resources for patients and caregivers

Patient Information

Patients who are starting post-remission treatment with ONUREG should be directed to the Patient Information for ONUREG

Review the Patient Information

ONUREG Patient Brochure

This comprehensive brochure includes practical tips written in patient-friendly language

Review the Patient Brochure

ONUREG Patient Brochure (Spanish)

A Spanish-language version of the ONUREG patient brochure is available

Review the Spanish-Language Brochure